Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 6/20 | 0.33 |
| ▸ | TACR3 | P29371 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25832880 | 0.85 | CYP19A1 (0.32) | CYP19A1TGFBR1 | |
| SCHEMBL17108201 | 0.84 | CYP19A1 (0.35) | CYP19A1LRRK2CCR1CCR8 | |
| SCHEMBL25847282 | 0.82 | BRD4 (0.38) | TGFBR1TACR3CCR1CCR8 | |
| SCHEMBL17108199 | 0.82 | CCR1 (0.53) | CYP19A1LRRK2TGFBR1CCR1CCR8 | |
| SCHEMBL12922238 | 0.78 | CCR1 (0.46) | TGFBR1TACR3CCR1CCR8THRB | |
| SCHEMBL17108200 | 0.78 | BTK (0.42) | TGFBR1 | |
| SCHEMBL15980637 | 0.74 | CYP19A1 (0.56) | CYP19A1DYRK1AIRAK4 | |
| SCHEMBL17108202 | 0.73 | FLT3 (0.54) | CYP19A1CCR1CCR8 | |
| SCHEMBL2621618 | 0.70 | IDO1 (0.37) | — | |
| SCHEMBL9963176 | 0.70 | CYP19A1 (0.66) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | CYP19A1 602/4885LRRK2 820/4885TGFBR1 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.